AVRO Avrobio Inc.

Avrobio Inc is a clinical stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose.

$0.98  +0.09 (9.55%)
As of 03/24/2023 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/21/2018
Outstanding shares:  43,774,088
Average volume:  364,998
Market cap:   $38,958,938
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BF2G3Y5

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%